Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma

The Effect of Omega-3 Fatty Acids on Bronchial Hyperresponsiveness, Sputum Eosinophilia, and Mast Cell Mediators in Asthma

“…We powered the study expecting a clinically important difference based on the existing studies showing a 64% protection in the percent fall in FEV 1 aft er exercise in subjects with asthma taking omega-3 fatty acids 5 and considering this inhibition to be similar to what has been observed using ICS on both exercise and mannitol in subjects with asthma. 17,29 Independent of ICS therapy, a patient with asthma who has a PD 15 will demonstrate considerable room for improvement in PD 15 in the presence of improved ICS treatment (higher dose or improvement in adherence) 17,30 and acute therapy using cromolyn drugs and b 2 -agonists. 11 A post hoc sample size analysis demonstrated that the individual treatment groups based on the presence of ICS therapy or b 2 -agonists as needed were either adequately powered or slightly underpowered, suggesting that a minimum of 12 to 13 subjects are required when using inhaled mannitol in a study assessing an intervention and looking for a minimal important difference of 1 doubling dose.…”

Asthma, outdoor air quality and the Olympic Games

“…45 Such tachyphylaxis to their bronchoprotective effects occurs after only a few days of use and is not antagonized by inhaled corticosteroid therapy, which can reduce exercise-induced bronchoconstriction in most people with asthma after a few weeks of regular use. 46 If asthma is not controlled by a low dose of inhaled corticosteroid therapy, current guidelines suggest that a long-acting β 2 -agonist should be prescribed to improve such control. Therapy with a leukotriene receptor antagonist, such as montelukast, is a second option for this purpose.…”

Ciclesonide in persistent asthma: the evidence of its therapeutic value

“…More recent data, however, show that compared with ciclesonide 160 mcg once daily, ciclesonide 320 mcg twice daily resulted in significantly improved PEF (P=0.0014) in 680 patients with severe asthma (Bateman et al 2006a). A dose-response effect was also demonstrated in a 3-week study investigating ciclesonide 40, 80, 160, and 320 mcg on exercise-induced bronchoconstriction in 26 patients with mild asthma (Subbarao et al 2006). Daily dosing given either in the morning or in the evening is associated with positive treatment response (Postma et al 2001).…”